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Sir, We read with interest the recently published study by Maguire and co-workers on the clinical utility of antinuclear antibody testing (ANA) in a real-world rheumatology setting (1) . By comparing indirect immunofluorescence (IF) microscopy with an enzyme-linked immunosorbent assay (ELISA), they reached the conclusion that ELISA is the preferable method. This subject is a matter of debate since many years (2, 3) . The opinion of Maguire and co-workers is based in their finding that sera from 169 patients (14%), out of 1239 analysed during a 12-month period, tested IF-positive but ELISA-negative. This result did not relate to self-reported symptoms suspect of systemic lupus erythematosus (SLE) or any other systemic inflammatory disease compared to age-and sex-matched controls testing ANA-negative with both IF and ELISA. However, we have a few objections to the study design. First and foremost, regarding ANA as a criterion for SLE, the 1982 ACR classification states that "an abnormal titer of antinuclear antibody by immunofluorescence or an equivalent technique" is required (4) . As shown in many studies, IF and ELISA are not equivalent regarding ANA results. Thus, at present only IF-ANA qualifies as an ACR classification criterion, but solely when it exceeds the cut-off limit for an abnormal antibody titre, i.e. in practice at a serum level above the 95 th percentile in a healthy blood donor material. Maguire and co-workers screened for IF-ANA at a serum dilution of 1:40. Assuming their IF test was performed with up-to-date equipment, screening for ANA at this high serum concentration will undoubtedly result in a huge number of positive reactions below abnormal titre (5,6). On the other hand, with an appropriate cut-off level for IF-ANA, the analysis is likely to result in a point prevalence of ANA far below 95% among patients with established SLE (7) . A caveat regarding the IF-ANA test used by Maguire and co-workers is that the secondary antibody in their diagnostic kit was achieved using whole human IgG molecules rather than IgG-Fc fragments. Thus, the fluorochrome-labelled detection antibody may recognize not only IgG, but also light chains of other immunoglobulin isotypes, potentially capturing also IgM-class ANA, which is more common than IgG-ANA among healthy blood donors (8) . Based upon >3000 serum samples sent for routine ANA testing, although not scrutinizing the clinical rationale to perform the test, we came to the conclusion that IgG-class specific IF-ANA must remain the gold standard for ANA screening (using proper cut-off limits), at least as long as the present ACR classification criteria are in use (5) . In their paper, Maguire and co-workers do not state the proportion of ELISA-positive sera testing IF-ANA negative. In our hands, this is a bigger problem than the reverse. Nevertheless, in addition to IF microscopy using HEp-2 or HEp-2000 cells as nuclear antigen substrates, we advocate the use of supplementary antigen-specific assays (e.g. ELISA) in order not to miss out patients positive for anti-SSA/Ro60 antibodies! 
